M
Maureen E. Trudeau
Researcher at Sunnybrook Health Sciences Centre
Publications - 259
Citations - 14303
Maureen E. Trudeau is an academic researcher from Sunnybrook Health Sciences Centre. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 51, co-authored 235 publications receiving 12424 citations. Previous affiliations of Maureen E. Trudeau include York University & Women's College Hospital.
Papers
More filters
Journal ArticleDOI
Impact of center case volume on cardiotoxicity during adjuvant trastuzumab in breast cancer.
Nicolas J. Chin-Yee,Andrew T. Yan,George Tomlinson,Craig C. Earle,Maureen E. Trudeau,Murray Krahn,Dennis T. Ko,Monika K. Krzyzanowska,Raveen Pal,Christine B. Brezden,Kelvin K. W. Chan +10 more
TL;DR: All breast cancer patients who were diagnosed in 2003-2009 in Ontario and treated with adjuvant T were identified through a provincial drug funding program, and linked to administrative databases to ascertain patient demographics, hospitalizations, cardiac risk factors, cardiac imaging, comorbidities, and treating centre and MD case volume.
Journal ArticleDOI
Pegylated liposomal doxorubicin (PLD) plus cyclophosphamide as 1st-line therapy for metastatic breast cancer in patients previously treated with anthracyclines
Maureen E. Trudeau,Louise Provencher,Lawrence Panasci,Louise Yelle,Jean Latreille,T. Vandenberg,Daniel Rayson,A. Rodgers,Jean-François Pouliot +8 more
TL;DR: A multi-center single arm phase II trial to assess the safety and efficacy of PLD 35mg/m2 in combination with cyclophosphamide 600 mg/ m2 every 3 weeks.
Journal ArticleDOI
The association between the transfer of emergency department admitted patients to inpatient hallways and outcomes of oncology patients
Charles Henry Lim,Matthew C. Cheung,Maureen E. Trudeau,Kevin Imrie,Ben De Mendonca,Simron Singh +5 more
TL;DR: The protocol for transferring ED admitted patients to inpatient hallway beds did not reduce ED length of stay for oncology patients; however, patient satisfaction was decreased.
Proceedings ArticleDOI
Reductions in tumor RNA integrity associated with clinical response to epirubicin/docetaxel chemotherapy in breast cancer patients.
Amadeo M. Parissenti,Judy-Anne W. Chapman,Harriette J. Kahn,Baoqing Guo,Lei Han,Patti O'Brien,Mark Clemons,Roberta A. Jong,Rebecca Dent,B Fitzgerald,Kathleen I. Pritchard,Lois E. Shepherd,Maureen E. Trudeau +12 more
TL;DR: The association of RIN with tumour extent, pathologic complete response, clinical response, a known risk factor (Topo II), and drug dose suggests that the RIN may represent an important new biomarker for measuring response to anthracycline/taxane combinations (and possible other chemotherapy regimens) in breast cancer patients.
Journal ArticleDOI
Pilot Study on the Utility of Circulating HER2/Neu Levels in the Serum of Breast Cancer Patients.
Sarah Morgan,Sarah Morgan,Yutaka Amemiya,Yutaka Amemiya,Elzbieta Slodkowska,Elzbieta Slodkowska,Fang-I Lu,Fang-I Lu,Carlos Parra-Herran,Carlos Parra-Herran,Sharon Nofech-Mozes,Sharon Nofech-Mozes,Maureen E. Trudeau,Ekaterina Olkhov-Mitsel,Arun Seth,Arun Seth,Wedad Hanna,Wedad Hanna +17 more
TL;DR: Findings suggest that post initial tissue diagnosis (tHER2), sHER2 assay may supplement subsequent tissue tests to monitor disease status and response to therapy, and further studies to assess the role of HER2 targeted therapies in sHER-positive/t HER2-negative cases upon disease progression are warranted.